University of Leeds and Lancaster University researchers have identified the enzyme PDE4B as a new target for Alzheimer's treatment.

Inhibition of PDE4B in a mouse model led to improved memory, healthier brain glucose metabolism, and reduced brain inflammation.

Results indicate that PDE4B activity reduction could be a beneficial strategy for treating Alzheimer's and possibly other dementias.

The study was published in the journal Neuropsychopharmacology and received support from various organizations.

Future research will focus on testing drugs that inhibit PDE4B for their effectiveness in treating Alzheimer's disease.